目的 探究多囊卵巢综合征不孕患者采用定经汤加减联合穴位埋线治疗的临床价值。方法 研究对象为我院2020年3月—2021年3月收治的90例多囊卵巢综合征不孕患者,并采取随机抽签法分为对照组和研究组,对照组枸橼酸氯米芬胶囊治疗,研究组采用定经汤加减联合穴位埋线法治疗。对比2组患者治疗效果。结果 对比2组患者激素水平,干预前,对照组患者睾酮素(T)、黄体生成激素(LH)、卵泡生成激素(FSH)水平与研究组差异不具有统计学意义(P>0.05);干预后,研究组在改善FSH、LH、T水平方面优于对照组(P<0.05);干预前,2组患者中医症状积分对比差异不具有统计学意义(P>0.05);干预后,研究组患者中医证候分析较对照组改善(P<0.05);对照组患者子宫内膜厚度、排卵率及妊娠率均低于研究组患者(P<0.05)。结论 定经汤加减联合穴位埋线能够有效改善多囊卵巢综合征不孕患者性激素水平,促进排卵、提高临床妊娠率,具备临床应用价值。

目的 分析多囊卵巢综合征患者性激素水平与胰岛素抵抗关系。方法 此次研究所设置的观察组对象为我院收入的多囊卵巢综合征患者,均在2017年5月—2020年7月入院,入选患者共100例。选取同一时期到我院进行相关检查的健康育龄女性100例作为对照组。分别检测、统计2组女性的性激素[包括性激素黄体生成素(LH)、睾酮(T)、雌二醇(E2)、卵泡刺激素(FSH)]、空腹血糖(FBG)、空腹胰岛素(FINS)以及胰岛素抵抗指数,对性激素水平与胰岛素抵抗关系进行分析。结果 相比于对照组,观察组女性的LH、T水平更高(P＜0.05),E2、FSH水平更低(P＜0.05),且FBG、FINS、胰岛素抵抗指数均更高(P＜0.05)。观察组中,胰岛素抵抗与非胰岛素抵抗患者的性激素水平与胰岛素抵抗指数,胰岛素抵抗女性与非胰岛素抵抗女性的LH、TE2、FSH水平均具有差异(P＜0.05)。LH、E2、FSH水平与胰岛素抵抗指数无相关性(P＞0.05),T水平与胰岛素抵抗指数呈正相关(P＜0.05)。结论 多囊卵巢综合征患者的性激素出现了一定的分泌紊乱现象,其中T水平与胰岛素抵抗具有相关性。

Objective To analyze the relationship between sex hormone levels and insulin resistance in patients with polycystic ovary syndrome. Methods The subjects of the observation group set up in this study were patients with polycystic ovary syndrome admitted to our hospital, all of whom were admitted from May 2017 to July 2020, and a total of 100 patients were enrolled.One hundred healthy women of childbearing age who came to our hospital for relevant examinations during the same period were selected as the control group.Sex hormone [including luteinizing hormone (LH), testosteron (T), estradiol (E2), follicle stimulating hormone (FSH)] levels, fasting blood glucose (FBG) level, fasting insulin (FINS) level, and insulin resistance index were detected and summerized in the two groups of women separately, and the relationship between sex hormone levels and insulin resistance was analyzed. Results Compared with the control group, women in the observation group had higher LH and T levels (P<0.05), lower E2 and FSH levels (P<0.05), and higher FBG, FINS levels, and insulin resistance index (P<0.05). In the observation group, sex hormone levels and insulin resistance index in insulin-resistant and non-insulin-resistant patients, and LH, TE2, and FSH levels in insulin-resistant and non-insulin-resistant women were different (P<0.05). There was no correlation between LH, E2, and FSH levels and insulin resistance index (P> 0.05), and T level were positively correlated with insulin resistance index (P<0.05). Conclusion Patients with polycystic ovary syndrome showed some disturbance in the secretion of sex hormones, among which T level were correlated with insulin resistance.

目的 探讨青春期多囊卵巢综合征(PCOS)患者血清抗苗勒管激素(AMH)与25(OH)D₃水平的相关性。方法 本研究选择在2019年1月—2020年12月在我院妇科门诊就诊的PCOS青春期女性79名,另选择同期体检的非PCOS健康对照85名。对所有受试者测量身高、体质量,计算体质量指数(BMI)。由诊治医生检查研究对象是否有痤疮、多毛以及月经情况。抽取静脉血检测黄体生成素、卵泡刺激素、总睾酮、硫酸脱氢表雄酮、抗苗勒管激素和 25(OH)D₃,将 25(OH)D₃分为不足[25(OH)D₃<30 ng/mL]和缺乏[25(OH)D₃<20 ng/mL]2组,对数据进行比较分析。结果 与健康对照组比较,PCOS组更容易发生月经稀发/闭经,其痤疮发生率较高(P值均<0.05)。体质量指数、AMH值、总睾酮和硫酸脱氢表雄酮的体内检出水平在PCOS组较高,而25(OH)D₃在PCOS组较低(P值均<0.05)。PCOS组的AMH与BMI和总睾酮呈正相关关系,与25(OH)D₃呈负相关关系(P值均<0.05)。25(OH)D₃缺乏组的AMH水平高于25(OH)D₃不足组,对照组和PCOS组的25(OH)D₃缺乏组的AMH水平均高于25(OH)D₃不足组,两两比较其差异有统计学意义(P值均<0.05)。健康对照组的25(OH)D₃缺乏率为67.1%(57/85),而PCOS组的25(OH)D₃缺乏率为96.2%(76/79),2组比较其差异有统计学意义(χ²=22.68,P<0.001)。结论 青春期多囊卵巢综合征患者体内 25(OH)D₃水平与AMH 水平显著相关。AMH 和25(OH)D₃可用于评估青春期PCOS发病风险的替代指标。

Objective To explore the correlation between serum anti-Müllerian hormone (AMH) and 25(OH)D₃ levels in adolescent patients with polycystic ovary syndrome (PCOS). Methods Seventy-nine adolescent girls with PCOS and 85 non-PCOS healthy controls who walked in the gynecological clinic of our hospital from January 2019 to December 2020 were selected. Height, weight were measured and body mass index (BMI) was calculated.Hirsutism, acne and menstruation were evaluated by doctors on all subjects. Venous blood was drawn to detect levels of luteinizing hormone, follicle stimulating hormone, total testosterone, dehydroepiandrosterone sulfate, AMH and 25(OH)D₃, 25(OH)D₃ was further divided into insufficient [25(OH)D₃<30 ng/mL] and deficient [25(OH)D₃<20 ng/mL]level, then all data were compared and analyzed between two groups. Results Compared with the healthy control group, the PCOS group was more prone to have oligomenorrhea or amenorrhea, the incidence of acne was higher in PCOS group than in control group (all P values<0.05). BMI, the levels of AMH, total testosterone and dehydroepiandrosterone sulfate were significantly higher in the PCOS group compared to the control group, while 25(OH)D₃ was the opposite (all P values <0.05). AMH in the PCOS group was positively correlated with BMI and level of total testosterone, and negatively correlated with 25(OH)D₃ (all P values<0.05). The AMH level in the 25(OH)D₃ deficiency group was higher than that in the 25(OH)D₃ insufficient group, the AMH levels of the 25(OH)D₃ deficient group and control group were higher than that in the 25(OH)D₃ insufficient group,the differences were statistically significant (P<0.05). The 25(OH)D₃ deficiency rate in the healthy control group was 67.1% (57/85), while the 25(OH)D₃ deficiency rate in the PCOS group was 96.2% (76/79). The difference between the two groups was statistically significant (χ²=22.68, P<0.001). Conclusions Serum 25(OH)D₃ level was an independent factor significantly associated with AMH level in adolescents with PCOS. AMH and 25(OH)D₃ levels may be used as surrogate markers of PCOS risk in adolescents.

目的 探究炔雌醇环丙孕酮联合胰岛素增敏剂治疗多囊卵巢综合征疗效。方法 选取广东省第一荣军医院妇科2018年8月—2020年8月收治的100例多囊卵巢综合征患者作为研究对象,采用随机数字表法将患者分为对照组(n=50)和观察组(n=50),2组患者均给予炔雌醇环丙孕酮治疗,观察组此外联合胰岛素增敏剂治疗,比较2组患者治疗前、治疗30 d后血清性激素、抗缪勒管激素(AMH)水平、代谢指标水平以及临床疗效(包括排卵、妊娠等)。结果 治疗前,2组患者血清性激素、AMH水平比较,差异不具有统计学意义(P>0.05),治疗后,2组患者AMH、血清性激素水平均有所下降,且观察组低于对照组(P<0.05)。治疗前,2组患者代谢指标比较,差异不具有统计学意义(P>0.05),治疗后2组患者代谢指标水平均有所下降,且观察组低于对照组(P<0.05)。观察组治疗有效率高于对照组(P<0.05)。结论 使用单一药物治疗具有局限性,将炔雌醇环丙孕酮与胰岛素增敏剂相联合治疗能够有效降低患者胰岛素代谢指标水平以及性激素水平,提高患者受孕几率,具有良好的治疗效果。

Objective To explore the efficacy of ethinylestradiol and cyproterone combined with insulin sensitizer in the treatment of polycystic ovary syndrome. Methods A total of 100 patients with polycystic ovary syndrome treated in the Department of Gynecology of the First Invalids Hospital of Guangdong Province from August 2018 to August 2020 were selected as the research object. The patients were divided into control group (n=50) and observation group (n=50). The patients in both groups were given ethinylestradiol cyproterone. In addition, the observation group was treated with insulin sensitizer. The levels of serum sex hormone, anti-Müllerian hormone (AMH), metabolic index level and clinical efficacy (including ovulation, pregnancy, etc.) before treatment and 30 days after treatment were compared. Results Before treatment, the levels of serum sex hormone and AMH had no significant difference between two groups (P>0.05). After treatment, the levels of AMH and serum sex hormone both decreased in two groups, and those in observation group were lower than those in control group (P<0.05). Before treatment, it had no significant difference in metabolic indexes (P>0.05). After treatment, the levels of metabolic indexes in the two groups decreased, and those in observation group were lower than those in control group (P<0.05). The effective rate of the observation group was higher than the control group (P<0.05). Conclusions Using single drug treatment has limitations. The combination of ethinylestradiol cyproterone and insulin sensitizer can reduce insulin metabolism and sex hormone levels, improve the probability of pregnancy, which have a good therapeutic effect.

目的 探究二甲双胍在多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者中的促排卵效果。方法 选取2019年1月—2020年12月收治的66例PCOS患者进行回顾性分析,以治疗方案为依据进行分组(对照组、观察组),对照组均采用炔雌醇环丙孕酮进行治疗(n=33),观察组则在其基础上联合二甲双胍进行治疗(n=33),对比两组患者的性激素水平[黄体酮生成素(luteinizing hormone,LH)、睾酮(testosterone,T)]、血糖指标[空腹血糖(fasting plasma glucose,FPG)、空腹胰岛素(fasting insulin,FINS)、胰岛素抵抗指数]及促排卵效果。结果 观察组在治疗后的LH、T水平均低于对照组(P＜0.05);且观察组在治疗后的FPG、FINS、胰岛素抵抗指数水平均低于对照组(P＜0.05);此外,经过治疗后,观察组患者的排卵率为54.5%,高于对照组的30.3%(P＜0.05)。结论 将二甲双胍应用于PCOS患者的治疗方案中,可显著改善其性激素水平及血糖代谢情况,促进排卵率的提升,在PCOS导致的不孕症治疗中具有积极的应用价值。

Objective To explore the effect of metformin on ovulation induction in patients with polycystic ovarian syndrome (PCOS). Methods A total of 66 cases of PCOS patients from January 2019 to December 2020 were retrospectively analyzed and divided into control group and observation group according to the treatment plan. The control group was treated with ethinylestradiol and cyproterone (n=33), while the observation group was treated with metformin additionally (n=33). The levels of sex hormone (luteinizing hormone,testosterone),the indexes of fasting plasma glucose (FPG), fasting insulin (FINS) and homeostasis model assessment for insulin resistance (HOMA-IR) in the two groups were compared. The effects of ovulation induction were evaluated. Results The hormone levels of the observation group after treatment were lower than those of the control group (P<0.05); and the FPG, FINS and HOMA-IR levels of the observation group after treatment were lower than those of the control group (P<0.05); in addition,the ovulation rate of the observation group was 54.5% after treatment, which was higher than that of the control group (30.3%, P<0.05). Conclusion Metformin in the treatment of PCOS patients could greatly improve their sex hormone levels and blood glucose metabolism, promote ovulation rate, and has application value in the treatment of infertility caused by PCOS.